NOV. 25th, 2020
Results Published from 2-Year Study of 229 Wounds Treated in an NHS Clinic Show Fluorescence Point-of-Care Imaging Improved Wound Healing Rates by 23%
TORONTO and LONDON, Nov. 25, 2020 – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced the publication of results from a 2-year retrospective study of 229 foot ulcers in Diagnostics. Diabetic foot ulcers represent a large and ever-increasing financial burden on the National Health Service (NHS), costing up to £962 million annually1. Antimicrobials account for a highly variable portion of these costs, due in part to the clinical challenges associated with diagnosing bacterial burden and selecting appropriate treatment2. Improved methods of evaluating bacterial burden in wounds are needed to facilitate more judicious use of antimicrobials and reduce the associated economic burden.